Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.46 |
| ▸ | PGR | P06401 | 4/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752781 | 0.99 | NR3C1 (0.45) | NR3C1PGRARADORA2ACYP3A4 | |
| SCHEMBL753726 | 0.93 | NR3C1 (0.42) | NR3C1PGRARADORA2A | |
| SCHEMBL752257 | 0.91 | NR3C1 (0.44) | NR3C1PGRARADORA2ACYP3A4 | |
| SCHEMBL753522 | 0.87 | NR3C1 (0.42) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL751845 | 0.87 | NR3C1 (0.42) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL752374 | 0.87 | NR3C1 (0.42) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL751387 | 0.87 | NR3C1 (0.42) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL753749 | 0.87 | NR3C1 (0.44) | NR3C1PGRAR | |
| SCHEMBL753464 | 0.85 | NR3C1 (0.44) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL754373 | 0.85 | NR3C1 (0.44) | NR3C1PGRARCYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222247-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222247-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2078015-B1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-07 | — | — | US | disclosed |
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | NR3C1, NFRKB, RELA | NR3C1 1/4885PGR 2359/4885AR 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.